GE HealthCare (GEHC) CTO awarded stock options and RSUs vesting through 2029

Rhea-AI Filing Summary

Kass-Hout Taha reported acquisition or exercise transactions in this Form 4 filing.

GE HealthCare Technologies Inc. reported that Chief Technology Officer Taha Kass-Hout received equity awards on March 2, 2026. He was granted an employee stock option for 34,847 shares and 13,254 shares of common stock as a restricted stock unit award, vesting in stages from September 2, 2027 through September 2, 2029.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kass-Hout Taha

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	34,847	$0.00	--
Grant/Award	Common Stock, par value $0.01 per share	13,254	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 34,847 shares (Direct); Common Stock, par value $0.01 per share — 92,909 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock. Award of restricted stock units with respect to GE HealthCare common stock, of which 33% will vest on September 2, 2027, 33% will vest on September 2, 2028, and 34% will vest on September 2, 2029. Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 2, 2027, 33% will become exercisable on September 2, 2028, and 34% will become exercisable on September 2, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kass-Hout Taha

(Last) (First) (Middle)

500 W. MONROE STREET

(Street)

CHICAGO IL 60661

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GE HealthCare Technologies Inc. [ GEHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.01 per share	03/02/2026		A		13,254(1)(2)	A	$0	92,909	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$80.16	03/02/2026		A		34,847		(3)	03/02/2036	Common Stock, par value $0.01 per share	34,847	$0(3)	34,847	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock.

2. Award of restricted stock units with respect to GE HealthCare common stock, of which 33% will vest on September 2, 2027, 33% will vest on September 2, 2028, and 34% will vest on September 2, 2029.

3. Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 2, 2027, 33% will become exercisable on September 2, 2028, and 34% will become exercisable on September 2, 2029.

Remarks:

	/s/ Frank R. Jimenez, General Counsel and Corporate Secretary, as attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did GEHC CTO Taha Kass-Hout report on March 2, 2026?

Taha Kass-Hout reported two equity awards on March 2, 2026: an employee stock option for 34,847 shares and a grant of 13,254 shares of common stock in restricted stock unit form, both awarded at no cash exercise price initially.

How many GE HealthCare (GEHC) stock options were granted to the CTO?

The CTO received an employee stock option covering 34,847 shares of GE HealthCare common stock. According to the disclosure, 33% of this option becomes exercisable on September 2, 2027, another 33% on September 2, 2028, and the remaining 34% on September 2, 2029.

What restricted stock unit award did GEHC grant to its CTO?

GE HealthCare granted the CTO 13,254 restricted stock units, each representing one share of common stock at settlement. The award vests 33% on September 2, 2027, another 33% on September 2, 2028, and 34% on September 2, 2029, subject to continued service conditions.

Does the Form 4 show a buy or sell of GEHC shares by the CTO?

The Form 4 reports only acquisitions through equity awards, not open-market buys or sales. Both transactions are coded as grants (code A), reflecting stock option and restricted stock unit awards, rather than discretionary purchases or sales in the market.

What is the ownership status of GEHC shares held by the CTO after these awards?

Following the common stock award, the CTO directly holds 92,909 shares of GE HealthCare common stock. This figure reflects his direct ownership after the 13,254-share restricted stock unit grant reported in the Form 4 for March 2, 2026.

How do the vesting schedules affect GEHC CTO’s ability to access these awards?

The awards vest over three years, limiting immediate access. Both the stock options and restricted stock units vest 33% in 2027, 33% in 2028, and 34% in 2029, meaning the CTO gains rights to portions gradually rather than all at once.